Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 2/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.36 |
| ▸ | HCRTR2 | O43614 | 5/20 | 0.35 |
| ▸ | HCRTR1 | O43613 | 3/20 | 0.35 |
| ▸ | IDO1 | P14902 | 4/20 | 0.35 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.35 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.35 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.35 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.33 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18343987 | 0.82 | HCRTR2 (0.36) | L3MBTL1HCRTR2HCRTR1SLC6A4SLC6A2 | |
| SCHEMBL6267005 | 0.77 | L3MBTL1 (0.39) | L3MBTL1SLC6A4SLC6A2SLC6A3 | |
| SCHEMBL7294198 | 0.77 | EPHX1 (0.55) | EPHX1IDO1SLC6A4SLC6A2SLC6A3 | |
| SCHEMBL20338123 | 0.77 | LPL (0.31) | HCRTR2HCRTR1SLC6A4SLC6A2SLC6A3 | |
| SCHEMBL1692211 | 0.76 | HCRTR2 (0.34) | L3MBTL1HCRTR2HCRTR1TMEM97SIGMAR1 | |
| SCHEMBL1692478 | 0.76 | HCRTR2 (0.34) | L3MBTL1HCRTR2HCRTR1TMEM97SIGMAR1 | |
| SCHEMBL14366914 | 0.75 | L3MBTL1 (0.39) | EPHX1L3MBTL1HCRTR2HCRTR1TMEM97 | |
| SCHEMBL1697504 | 0.75 | CHRNB4 (0.38) | L3MBTL1HCRTR2HCRTR1TMEM97SIGMAR1 | |
| SCHEMBL15308831 | 0.75 | CHRNB4 (0.38) | L3MBTL1HCRTR2HCRTR1TMEM97SIGMAR1 | |
| SCHEMBL15308721 | 0.75 | CHRNB4 (0.38) | L3MBTL1HCRTR2HCRTR1TMEM97SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8119653-B2 | Belactosin derivatives as therapeutic agents/biological probes and their synthesis | THE TEXAS A&M UNIVERSITY SYSTEM (US) | 2012-02-21 | — | — | US | disclosed |
| US-20090042922-A1 | NOVEL BELACTOSIN DERIVATIVES AS THERAPEUTIC AGENTS/BIOLOGICAL PROBES AND THEIR SYNTHESIS | NATIONAL SCIENCE FOUNDATION | 2009-02-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090042922-A1 | NOVEL BELACTOSIN DERIVATIVES AS THERAPEUTIC AGENTS/BIOLOGICAL PROBES AND THEIR SYNTHESIS | PSMB1, PSMB10, PBK | EPHX1 4197/4885L3MBTL1 125/4885HCRTR2 4468/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.